Leap Therapeutics (LPTX) said Wednesday that updated findings from its phase 2 trial indicate that sirexatamab combined with bevacizumab and chemotherapy improves progression-free survival and overall response rate in patients with advanced colorectal cancer.
Leap reported that patients with elevated DKK1 protein levels who were treated with sirexatamab in addition to bevacizumab and chemotherapy had a 32% higher overall response rate and lived 3.5 months longer without their cancer worsening compared with patients receiving only bevacizumab and chemotherapy.
The company also said that patients who had not previously received anti-VEGF therapy saw a 22% higher ORR and lived 2.6 months longer without disease progression, though overall survival data is still being collected.
The company said the new data supports plans to move sirexatamab into a phase 3 trial, focusing on colorectal cancer patients with elevated DKK1 protein levels or no prior anti-VEGF therapy.
The company's shares were up more than 18% in recent Wednesday premarket activity.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。